Kvantify Completes 2nd Close of €7M Round to Advance Quantum Drug Discovery

Key Takeaways

• €7M round closed, led by EIC Fund, Delphinus VC.
• Qrunch platform enables quantum chemistry on current hardware.
• Funding accelerates market expansion and pharma collaborations.
• Quantum computing may cut drug R&D costs dramatically.
• Kvantify positions Europe as quantum‑driven biotech leader.

Summary

Kvantify announced the second close of its €7 million funding round, with the European Innovation Council Fund and Denmark’s Delphinus Venture Capital as lead investors. The capital will support the rollout of its Qrunch platform, which runs quantum chemistry workloads on existing quantum hardware, and broaden partnerships with drug‑discovery firms. Launched in November 2025, Qrunch aims to deliver realistic molecular simulations that classical computers struggle with. The infusion positions Kvantify to accelerate its roadmap and strengthen Europe’s quantum‑driven life‑science ecosystem.

Pulse Analysis

Quantum computing promises to tackle the exponential complexity of molecular simulations that underpin early‑stage drug discovery. Traditional classical methods often hit scalability limits, leaving many promising compounds unexplored. Kvantify’s Qrunch platform bridges this gap by translating quantum chemistry problems onto today’s noisy intermediate‑scale quantum (NISQ) devices, delivering more accurate energy estimates and reaction pathways. By integrating quantum and classical workflows, the company aims to accelerate hit identification and reduce false‑positive rates that inflate development costs.

The €7 million second‑close, anchored by the European Innovation Council Fund and Delphinus Venture Capital, signals strong institutional confidence in Kvantify’s approach. The funding will be deployed to expand sales and business‑development teams, forge deeper collaborations with pharmaceutical R&D groups, and enhance the Qrunch software stack for broader usability. This capital injection also supports scaling of cloud‑based quantum resources, ensuring customers can run realistic workloads without owning quantum hardware outright, thereby lowering entry barriers for biotech firms.

For the European life‑science sector, Kvantify’s progress underscores a strategic shift toward quantum‑enabled drug pipelines. As regulatory bodies and investors increasingly prioritize innovative R&D models, the ability to predict molecular behavior with quantum precision could translate into faster clinical timelines and reduced attrition. Europe’s coordinated investment through the EIC Fund positions the region to become a hub for quantum‑driven biotech, potentially attracting talent, partnerships, and downstream manufacturing opportunities. In the longer term, successful commercialization of Qrunch may catalyze a new class of medicines that were previously computationally infeasible.